Stockreport

Bavarian Nordic launches Phase 1/2 study of prime/boost vaccine CV301 in colorectal and pancreatic cancers [Seeking Alpha]

BAVARIAN NORDIC R/I S/ADR  (BVNRY) 
NASDAQ:AMEX Investor Relations: bavarian-nordic.com/investor.aspx
PDF Dosing is underway in a Phase 1/2 clinical trial evaluating Bavarian Nordic A/S's ( OTCPK:BVNKF ) CV301, combined with AstraZeneca's ( AZN ) PD-L1 inhibi [Read more]